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8 Abstract
9 Background We assessed differences in predicted breast
10 cancer (BC) mortality rates, across Europe, by 2020, taking
11 into account changes in the time trends of BC mortality
12 rates during the period 2000–2010.
13 Methods BC mortality data, for 27 European Union (EU)
14 countries, were extracted from the World Health Organi-
15 zation mortality database. First, we compared BC mortality
16 data between time periods 2000–2004 and 2006–2010
17 through standardized mortality ratios (SMRs) and carrying
18 out a graphical assessment of the age-specific rates. Sec-
19 ond, making use of the base period 2006–2012, we pre-
20 dicted BC mortality rates by 2020. Finally, making use of
21 the SMRs and the predicted data, we identified a clustering
22 of countries, assessing differences in the time trends
23 between the areas defined in this clustering.
24Results The clustering approach identified two clusters of
25countries: the first cluster were countries where BC pre-
26dicted mortality rates, in 2020, might slightly increase
27among women aged 69 and older compared with 2010
28[Greece (SMR 1.01), Croatia (SMR 1.02), Latvia (SMR
291.15), Poland (SMR 1.14), Estonia (SMR 1.16), Bulgaria
30(SMR 1.13), Lithuania (SMR 1.03) and Slovakia (SMR
311.06)]. The second cluster was those countries where BC
32mortality rates level off or decrease in all age groups (re-
33maining countries). However, BC mortality rates between
34these clusters might diminish and converge to similar fig-
35ures by 2020.
36Conclusions For the year 2020, our predictions have
37shown a converging pattern of BC mortality rates between
38European regions. Reducing disparities, in access to
39screening and treatment, could have a substantial effect in
40countries where a non-decreasing trend in age-specific BC
41mortality rates has been predicted. 2
43Keywords Breast cancer  Europe  Mortality 
44Projections  Time trends  Screening
45Introduction
46Recent estimates have shown that breast cancer (BC) is still
47the most frequently reported cancer among European
48women [1]. However, changes in the burden of cancer
49mortality are expected to be observed across Europe in the
50short term, with BC mortality rates surpassed by those of
51lung cancer among young age groups [2]. These changes
52are related to improvements in survival due to the efficacy
53of treatments in parallel with earlier detection of cancer
54with screening [3]. Previous studies in Europe have not
55assessed, with precision, what amount of variability in
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56 mortality is due to screening and/or treatment [4]. It is
57 likely that the variation observed in the BC burden across
58 Europe is attributable to various screening activities in
59 operation, differences in diagnosis and treatment, and in
60 the distribution of known risk factors for BC [4].
61 In 2003, the European Parliament (EP) adopted a Res-
62 olution (A5-0159/2003) which aims to diminish disparities
63 in access to BC screening and treatment [5]. Since then,
64 improvements have been observed in BC survival in some
65 countries, notably in western and northern countries, and
66 this has acted as an incentive for new members of the EU,
67 and other Eastern European countries, to reduce health
68 inequalities in access to screening and treatment, and thus
69 reduce the gaps in BC mortality trends [3, 6].
70 In this study, we examined changes in the variability of
71 BC mortality patterns in EU-27 countries, during the period
72 2000–2010, comparing two 5-year periods: 2000–2004 and
73 2006–2010. Finally, making use of the most recent trends
74 in BC mortality rates, we compared the observed BC
75 mortality rates, in 2010, with rates predicted for 2020 and
76 identified two clusters of countries associated with these
77 patterns of BC mortality.
78 Methods
79 Data
80 Data on BC mortality were extracted from the World
81 Health Organization mortality database for 27 countries in
82 Europe during the period 1990–2012 [7].
83 Age-specific BC mortality rates and age-standardised
84 mortality rates (ASMRs) to the World Standard Population
85 were calculated for all countries. In cases where age-
86 specific data were missing, rates were estimated through
87 linear interpolation. The latter was performed for Belgium
88 (2000–2002), Italy (2004–2005), Portugal (2004–2006),
89 and Poland (1997–1998). Data for Slovenia were available
90 for 2010 and BC mortality data in 2011–2012 were esti-
91 mated by applying the BC age-specific rates in 2010 to the
92 population distribution in 2011–2012. Finally, BC mortal-
93 ity data for Slovakia in 1990 were computed as the mean of
94 the age-specific rates between 1992 and 1993. Based on
95 these data, we carried out four statistical models, within the
96 Bayesian framework, assuming that the number of deaths
97 follows a Poisson distribution. Breast cancer mortality data
98 were arranged in eighteen 5-year age groups (from 0–4 to
99 85–90 years) throughout the analysis.
100 Data on national populations were extracted from the
101 Eurostat Database, maintained by the European Commis-
102 sion [8]. The latter takes into account age-specific mortality
103 rates and international net migration.
104Analytical approach
105Changes in the BC mortality rates comparing the periods
1062000–2004 and 2006–2010 All the calculations assumed
107a Poisson distribution for the number of deaths under a
108Bayesian approach [9], as an extension of the classic pre-
109dictive method.
110Standardized mortality ratios (SMRs) were calculated to
111compare the risk of dying from BC in different periods.
112The ratios were computed as the number of observed BC
113deaths, in a given period, with the number of expected BC
114deaths if the age-specific death rates were the same as in
115another (reference) period. The SMR was used to compare
116the risk of death from BC in 2006–2010 with respect to
1172000–2004. The SMRs were calculated for the whole data,
118for women aged 50–69 years and those 70 years or older.
119Graphical assessment of the changes in the age-specific BC
120mortality rates comparing the periods 2000–2004 and
1212006–2010 Age-specific mortality rates were smoothed
122through an autoregressive Bayesian model imposing a
123temporal structure on model parameters [10]. We assumed
124that the number of deaths from BC, i.e. D, followed a
125Poisson distribution, Dip Poisson ðlipÞ, where i refers to
126the ith age group, i ¼ f1; 2; . . .; 17; 18g j f0 4; 5
1279; . . .; 80 84; 85 89g and p is the period, p = {1,
1282} | {2000–2004, 2006–2010}. Assuming that the expected
129age-specific BC mortality rate is kip ¼
lip
Ypt
, where Ypt are the
130person-years at risk, we smoothed these rates through the
131model logðkipÞ ¼ cþ aip where aip are the age-specific
132effects and c an intercept which guarantees
P
i aip ¼ 0. To
133smooth rates, we imposed a temporal autoregressive
134structure of order 2 for the age effects [10]
135aipNðai1p; spÞ where sp is the prior precision for which
136we assumed spGammað0:001; 0:001Þ. Once the model
137was fitted, we simulated the posterior distribution of
138ki;20062010 and ki;20002004 and then we obtained a posterior
139distribution of hi ¼
ki;20062010
ki;20002004
, which is the ratio of age-
140specific BC mortality rates between periods.
141Projections of breast cancer mortality in 2020 and cluster
142analysis Making use of the eighteen 5-year age groups
143(from 0–4 to 85–90 years), for the prediction base of
1442006–2012, rates were projected to 2020 using a Bayesian
145log-linear age-specific model for each country [9]. Based
146on previous experience, the choice of a minimum predic-
147tion base length of 5 years can be considered adequate for
148projections [9]. Projections were made by extrapolating the
149rates of the model fitted to 2006–2012 to the unobserved
150years 2013–2020 and plugging in the age-specific popula-
151tion counts for those years to obtain the predicted number
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152 of deaths [9]. The use of these population counts is needed
153 since these include the changes in age distribution which
154 may affect future predictions [9, 10]. Therefore, the model
155 took into account changes in age distribution for the period
156 2013–2020. These population counts were obtained from
157 the United Nations World Population Prospects for the
158 years 2013–2020 [11].
159 Finally, we assessed changes in the risk of death from
160 BC comparing the years 2010 and 2020 by groups of
161 countries through a weighted clustering analysis. Making
162 use of the predicted number of BC deaths during 2020, for
163 each country, we estimated the ASMRs during 2020 and
164 the SMR in 2020 using as reference population that of
165 2010. Aggregating the ASMRs and SMRs, in a data set,
166 during the whole study period, a hierarchical weighted
167 clustering analysis (making use of the Ward aggregating
168 method) was used to identify clusters of countries [12].
169 Reporting and interpretation of results
170 Based on the posterior distribution of the estimates, we
171 calculated the 95% credible intervals (95% CI) for SMRs
172 and age-specific ratios. For a 95% CI, the value of interest
173 SMR or age-specific ratio lies with a 95% probability in the
174interval. On the other hand, the 95% prediction interval of
175the age-specific deaths for 2020 was used for prediction
176purposes. All the analyses were carried out through R using
177the library INLA [13] (See supplementary material for
178additional Figures and R code).
179Results are presented by grouping countries by European
180regions. Population screening programmes as a reference for
181the interpretation of the data are summarized in the Supple-
182mentaryMaterial (see section: ‘‘The situation ofBC screening
183programmes in the European countries considered in this
184study’’ and Table S2). The division in European regions was
185North, Western, Southern and Eastern European countries
186according to the United Nations geo scheme for Europe cre-
187ated by the United Nations Statistics division (https://unstats.
188un.org/unsd/methodology/m49/).
189In the presentation of results, we marked those countries
190where screening activities were introduced after 2005 [5].
191For those countries with screening activities, Figs. 1, 2, 3
192and 4 include vertical lines corresponding to age groups
193included in the screening programmes. To help with the
194interpretation of the results presented in these figures, the
195start of screening activities in each country and the target
196age groups must be taken into account. For this purpose,
197see Table S1 of the Supplementary material.
95% Credible Interval of the Rate Ratio 
*Vertical lines: age groups considered in the screening program.
* 
Screening Programs were initiated after 2005.  
Fig. 1 Age-specific ratio of breast cancer mortality rates comparing the time periods 2000–2004 (reference) and 2006–2010: Northwestern
European countries
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198 Results
199 Table 1 presents the SMRs for the periods 2000–2004 and
200 2006–2010 by the age groups 50–69 and [69 years.
201 Among women aged 50–69, we found a levelling off
202 towards a decrease in the risk of death from BC in the
203 countries considered (SMRs B 1). However, during
204 2006–2010 and among women aged 69 and older, there
205 was a higher risk of death (results in bold, Table 1) in
206 Greece (1.15%), Croatia (1.13%), Latvia (1.24%), Poland
207 (1.11%) and Romania (1.12%).
208 These results are graphically depicted in 5-year age
209 groups in Figs. 1 and 2 and focus on the age groups
210 included in the screening programmes which started before
211 2005. In those age groups where the 95% CI lies below 1,
212 the BC mortality rate in 2006–2010 is lower than its
213 2000–2004 counterpart. We must interpret higher mortality
214 in 2006–2010 with respect to 2000–2004 where the 95% CI
215 lies above 1. On the other hand, if the 95% CI includes 1, it
216 must be interpreted as no change in BC mortality rates
217 between time periods. Rate ratios were clearly below 1 in
218 most European countries (mortality rates during
219 2006–2010 lower than those during 2000–2004) in the age
220groups included in the screening programmes, with the
221exception of Latvia (ages 50–69), Lithuania (ages 50–69),
222Greece (ages 40–69 years) and Croatia (ages 50–69)
223(Fig. 2).
224Figures 3 and 4 compare the BC mortality rates for 2010
225and the 95% prediction interval for the age-specific BC
226mortality rates for 2020. The decreasing trend of BC
227mortality detected during 2000–2010 could level off by
2282020 in these countries where the 95% prediction intervals
229for BC mortality rates in 2020 include the observed BC
230mortality rates in 2010. In those age groups where the 95%
231prediction interval lies below the observed rates in 2010, a
232decrease in BC mortality rates is expected by 2020. Given
233this observation, for some of the northwestern countries
234(Fig. 3), the predicted BC mortality rates might decrease
235compared with 2010. This is the case for Denmark
236(50–59 years), Ireland (60–69 years), the Netherlands
237(45–64 years), Sweden (40–64 years) and UK
238(50–69 years). In Eastern European countries (Fig. 4), a
239similar trend might occur in the Czech Republic
240([45 years) and Hungary (45–64 years). BC mortality
241rates might increase in advanced age groups (beyond
24269 years of age) in Estonia, Latvia and Lithuania (see
95% Credible Interval of the Rate Ratio
*Vertical lines: age groups considered in the screening program. 
*
*
*
*
Screening Programs were initiated after 2005. 
Fig. 2 Age-specific ratio of breast cancer mortality rates comparing the time periods 2000–2004 (reference) and 2006–2010: Southern and
Eastern European countries
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243 Fig. 3), and in Greece, Croatia, Bulgaria, Poland, Romania
244 and Slovakia (see Fig. 4).
245 Cluster analysis
246 Making use of the predicted number of BC deaths during
247 2013–2020 we estimated the ASMRs for this time period. In
248 addition, we evaluated the changes in the risk of death from
249 BC between 2010 and 2020 calculating the SMR in 2020
250 with respect to 2010 (see Supplementary Table S1).We used
251 ASMRs and SMR data in a weighted clustering analysis
252 where our dataset included six columns: (1) ASMRs (50–69)
253 years in 2010, (2) ASMRs (50–69) years in 2020, (3)
254 ASMRs[69 years in 2010, (4) ASMRs[69 years in 2020,
255 (5) SMR (50–69) years and (6) SMR[69 years. The clus-
256 tering analysis identified two groups of countries (see
257 Fig. 5a, where one of the clusters included Estonia, Latvia
258 and Lithuania, Greece, Croatia, Bulgaria, Poland, Romania
259 and Slovakia. Figure 5b, c shows that the differences in the
260 time trend of BCmortality rates between these two groups of
261 countries might disappear by 2020 since ASMRs might
262 converge towards similar values.
263Discussion
264This study has shown that predicted BC mortality rates
265may have different trends depending on the country and
266European Region. Our predictions by 2020 show two pat-
267terns of BC mortality trends: (1) a non-decreasing trend
268mainly due to the increase in BC mortality rates from 2010
269among women[69 years, detected in nine countries, eight
270out of these from Eastern Europe, and (2) a decrease
271towards a plateau of these rates in the remaining countries.
272This divergence could mean that BC mortality rates
273between European regions might diminish and converge
274towards similar values by 2020. However, one must take
275into account that differences between countries still
276remain.
277Several limitations should be noted. First, BC mortality
278trends depend on previous trends in both incidence and
279survival [14]; therefore, using information on the time
280trends of these factors could lead to better interpretation of
281BC mortality predictions. We interpret our results taking
282into account this limitation. Second, a major limitation of
283the model is that it assumes a stability of a large amount of
95% Prediction Interval of  Breast Cancer mortality rates for 2020
*
*
Screening Programs were initiated after 2005. 
*
Observed Breast Cancer mortality rates in 2010
Rate: Rate per 100,000 women-years
*Vertical lines: age groups considered in the screening program. 
Fig. 3 Age-specific 95% prediction intervals of breast cancer mortality rates for 2020 compared with the observed breast cancer mortality rates
in 2010: Northwestern European countries
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284 variables such as the economic situation and, related to
285 this, universal access to the healthcare system. Taking this
286 limitation into account differences in the targeted popula-
287 tion that is screened could explain the differences between
288 countries and also the impact on the BC mortality predic-
289 tions. Changes of these variables may affect the predictions
290 presented here.
291 The most recent estimates of cancer incidence and sur-
292 vival in Europe have shown that some Eastern European
293 countries have the lowest BC incidence rates [4] and the
294 lowest 5-year relative survival of BC among European
295 countries [15]. In Bulgaria, Czech Republic, Poland, Slo-
296 vakia, Estonia, Latvia and Lithuania, BC incidence rates
297 rose during 1998–2007 among women aged 50–74 [4]
298 whereas 5-year relative survival remained below the
299 European average during a similar time period [15]. The
300 Czech Republic shows the highest BC incidence and sur-
301 vival rates among these countries [15]. Therefore, our
302 results suggest that the combined effect of BC diagnosis,
303 treatment, management and organization of BC care, and
304 differences in BC incidence between countries, may
305influence the variability observed in BC mortality rates
306[1, 16, 17].
307We found that, in most European countries, rate ratios
308were clearly below 1 when comparing BC mortality rates
309in 2006–2010 with those during 2000–2004 (reference
310period). In addition, advancements in breast cancer treat-
311ment, such as oestrogen therapy and adjuvant chemother-
312apy, and advancements in radiotherapy and surgery [1],
313have contributed to a decreasing trend in BC mortality
314rates. Selective oestrogen receptor modulators (such as
315tamoxifen and raloxifene) have also been assessed for
316primary prevention of breast cancer although their impact
317on mortality is likely to be limited since the chemopre-
318ventive use of these drugs has been uncommon [16]. As
319stated above, the implementation of organized or oppor-
320tunistic breast cancer screening in many European coun-
321tries is a key factor in explaining BC trends [4]. Organized
322mammographic screening aims to detect cancer at an ear-
323lier stage and thus reduce the incidence of advanced cancer
324[18] and could improve participation and equity of access
325[19–25]. Some other studies, however, have suggested that
*Vertical lines: age groups considered in the screening program. 
Observed Breast Cancer mortality rates in 2010 Rate: Rate per 100,000 women-years
95% Prediction Interval  of  Breast Cancer mortality rates for 2020
*
Screening Programs were initiated after 2005. 
*
*
*
Fig. 4 Age-specific predicted rates of breast cancer mortality in 2020 compared with the observed rates in 2010: Southern and Eastern European
countries
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326 a percentage of screening programmes associated with
327 early detection might have less impact than treatment in
328 reducing risk of death from this tumour [26, 27]. Uncer-
329 tainty about the magnitude of the effect of screening on BC
330 mortality reduction has been discussed elsewhere [27–30].
331 It is important to point out that the most recent cancer
332 mortality trends and predictions in Europe have shown, in
333 general, that BC deaths are declining towards a plateau in
334 the EU [2]. In the short term, other cancer sites, such as
335 lung cancer [1, 2], may surpass the breast, as the leading
336 cancer mortality site in middle-aged women. Our predic-
337 tions have shown that in Estonia, Latvia and Lithuania,
338Greece, Croatia, Bulgaria, Poland, Romania and Slovakia,
339BC mortality rates in 2020 might be higher than those rates
340in 2010. An explanation could be a rise of BC incidence
341combined with stabilization of BC survival [4, 15] in these
342countries. As a result, the predicted slight increase of BC
343mortality in these countries may lead to converging BC
344mortality rates among European countries, as our clustering
345analysis has shown.
346A limitation of our study is that predictions were made
347using the last year with available data for all countries
348considered, i.e. 2012. The availability of the most recent
349estimates of future population distributions could show a
Table 1 Standardized mortality ratios (SMR) and number of deaths from breast cancer comparing time periods 2000–2004 versus 2006–2010
50–69 years [69 years All ages
2000–2004 2006–2010 SMR 2000–2004 2006–2010 SMR 2000–2004 2006–2010 SMR
(N**) (N**) (N**) (N**) (N**) (N**)
Northern and Western Europe
Finland 327 360 0.91 394 442 0.97 827 882 0.93
Ireland 287 253 0.70 272 336 1.04 666 671 0.81
Luxembourg 34 31 0.71 31 54 1.02 82 93 0.95
Netherlands 1296 1300 0.82 1711 1569 0.80 3423 3221 0.81
Sweden 549 522 0.84 810 767 0.92 1521 1392 0.84
UK 4590 3893 0.71 6690 6565 0.91 12,771 11,572 0.82
Denmark 540 491 0.71 662 655 0.96 1334 1224 0.82
France* 3977 4232 0.88 5611 6613 0.98 11,011 12,013 0.90
Austria 569 484 0.80 967 881 0.82 1671 1501 0.78
Belgium 945 855 0.81 1234 1371 0.94 2441 2431 0.88
Germany 6956 5831 0.82 9293 10,471 0.95 18,071 17,721 0.87
Estonia 134 92 0.70 87 111 1.11 275 222 0.73
Latvia 202 183 0.95 133 192 1.24* 407 411 1.07*
Lithuania 271 227 0.91 195 244 1.07 547 521 0.92
Southern Europe
Spain 2080 2020 0.83 2850 3581 0.98 5676 6366 0.90
Italy 4396 3881 0.83 5814 7066 0.97 11,351 12,144 0.90
Portugal 581 623 1.00 699 820 0.95 1514 1631 0.91
Greece 661 601 0.91 797 1232 1.15* 1601 2019 1.12*
Malta 49 31 0.56 41 42 0.74 91 79 0.61
Croatia 343 339 0.95 401 553 1.13* 846 971 1.05*
Slovenia 148 131 0.82 191 247 0.94 366 414 0.94
Eastern Europe
Czech Rep. 791 661 0.71 1021 891 0.73 1961 1678 0.71
Hungary 997 795 0.73 1022 1071 0.87 2321 2028 0.88
Bulgaria 543 543 0.94 414 473 0.98 1156 1125 0.89
Poland 2120 2335 0.90 1804 2312 1.11* 4717 5171 0.99
Romania 1463 1401 0.91 999 1414 1.12* 2976 3171 0.99
Slovakia 391 342 0.81 357 391 0.92 811 795 0.89
In Bold * 95% credible interval of SMRs does not include 1, showing increasing risk between periods, (N**)median number of BC deaths within
the time period
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350 slightly different scenario since major differences were
351 found in women at advanced age. Large changes in pop-
352 ulation distributions, and their effect on cancer mortality,
353 are expected to be observed when populations’ prediction
354 surpasses 10 years [9].
355 Diminishing disparities in access to BC screening and
356 treatment is also the goal of the European Parliament
357 Resolution (A5-0159/2003), mentioned in the introduction.
358 Further development of these policies must be supported,
359 as evidence clearly shows that such policies have a positive
360 impact on population health.
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